The strongest serological correlate for lupus nephritis is antibody to double-stranded DNA although the mechanism by which anti-DNA antibodies initiate lupus nephritis is unresolved. Most recent reports indicate that anti-DNA must bind chromatin in the glomerular basement membrane or mesangial matrix to form glomerular deposits. Here we determined whether direct binding of anti-DNA antibody to glomerular basement membrane is critical to initiate glomerular binding of anti-DNA in experimental lupus nephritis. Mice were co-injected with IgG monoclonal antibodies or hybridomas with similar specificity for DNA and chromatin but different IgG subclass and different relative affinity for basement membrane. Only anti-DNA antibodies that bound basement membrane bound to glomeruli, activated complement, and induced proteinuria whether injected alone or co-injected with a non-basement membrane-binding anti-DNA antibody. Basement membrane-binding anti-DNA antibodies co-localized with heparan sulfate proteoglycan in glomerular basement membrane and mesangial matrix but not with chromatin. Thus, direct binding of anti-DNA antibody to antigens in the glomerular basement membrane or mesangial matrix may be critical to initiate glomerular inflammation. This may accelerate and exacerbate glomerular immune complex formation in human and murine lupus nephritis.
Introduction
The contribution of anti-DNA antibody to glomerulonephritis in mouse (1) and human (2) systemic lupus erythematosus (SLE) is well established. Although anti-double-stranded DNA (dsDNA) antibody is the best serological correlate for lupus nephritis (3, 4) , the frequent lack of correlation between serum anti-dsDNA and glomerulonephritis is a long Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms recognized conundrum in the clinical evaluation of individual SLE patients (3, 5, 6) . The lack of correlation between anti-dsDNA and lupus nephritis within individual patients may be a consequence of how anti-dsDNA antibodies bind in the glomerulus and initiate glomerulonephritis (6), a process not yet fully resolved (7) . Mechanisms proposed to explain glomerular deposition of anti-DNA antibody include glomerular binding of soluble immune complexes of nucleosomes and IgG anti-DNA (2, (8) (9) (10) , in situ formation of immune complexes when anti-DNA antibody binds to chromatin that has bound to glomerular basement membrane (GBM) or mesangial matrix (MM) (11) (12) (13) (14) (15) (16) (17) , and direct binding of anti-DNA antibody that cross-reacts with GBM or cell surface antigens (18) (19) (20) (21) (22) (23) (24) (25) . Recent morphologic studies (12) (13) (14) 16 ) have identified chromatin and IgG within the glomerular subendothelial and subepithelial electron dense deposits (EDS) in nephritic kidneys from lupus patients (26) and lupus-prone mice (27) . The recent results were interpreted to indicate that anti-DNA antibody could form glomerular deposits only when bound to chromatin or nucleosomes (28) (29) (30) .
The present experiments were designed to test the hypothesis that initial glomerular binding of anti-DNA antibody in lupus nephritis is a function of direct, cross-reactive binding to glomerular antigens, particularly in GBM or MM, and independent of DNA, nucleosomes, or chromatin. The experiments took advantage of a panel of anti-DNA monoclonal antibodies (mAbs) with similar relative affinities for DNA and chromatin but different relative affinities for basement membrane (BM) antigens in GBM and MM. Only anti-DNA mAbs that also bound BM antigens bound glomeruli in vivo and induced proteinuria. Glomerular binding of the anti-DNA mAbs was independent of DNA, nucleosomes, or chromatin. The results may explain why some anti-DNA mAbs are very effective at inducing lupus nephritis, but others are not. Similarly, the results may help to explain why SLE patients with similar serum anti-dsDNA antibody may have different susceptibility for lupus nephritis.
Results

In vitro binding of anti-DNA mAb to BM
Culture supernatants from 69 autoimmune anti-DNA mAbs from eight different (NZB × NZW)F 1 mice (BWF1) were randomly selected for analysis (Table 1) . Total IgG and relative affinity for binding to ssDNA, dsDNA, chromatin, and BM were quantified for each supernatant. The mAbs were stratified by relative affinity for BM into four different specificity groups (Table 1) . There is a significant difference among the four specificity groups for competitive binding to ssDNA and dsDNA and direct binding to BM but not for direct binding to chromatin. There is a strong and highly significant correlation between binding to BM and binding to dsDNA and a moderate, highly significant inverse correlation between binding to BM and binding to ssDNA. Anti-DNA mAbs that bound best to dsDNA are generally the mAbs that also bound best to BM. The correlation between BM and chromatin binding, although significant, was low compared to that for BM and dsDNA. The results indicate that mAbs with high relative affinity for dsDNA are more likely to bind BM than mAbs with high relative affinity for ssDNA. The results also indicate that anti-DNA mAb binding to BM is unrelated to relative affinity for chromatin.
The correlations between mAb binding to DNA and chromatin versus their potential to bind BM were further confirmed with purified mAbs (Table 2) . BM binding by purified mAbs was independent of relative binding affinity for dsDNA, chromatin, or nucleosomes since 163p.132, 452s.160, DNA3, and 3H9 mAbs bound nucleosomes and/or chromatin with high relative affinity but bound poorly or not at all to BM. MAb 452s.46 bound dsDNA with high relative affinity but did not bind BM. DNA6 mAb bound chromatin similarly to 163p.132 and DNA3 but unlike 163p.132 and DNA3, DNA6 also bound to BM. MAbs 163p.64, 163p. 77, and 163p.124 had 20-650 fold higher relative affinity for BM than for nucleosomes. Binding to BM was also independent of mAb pI. These results further indicate that anti-DNA mAb binding to BM is correlated with dsDNA binding and to lesser extent chromatin binding, but is independent of both for binding to BM.
Since previous investigators had concluded that anti-dsDNA mAb binding to BM was consequential to nucleosome contamination of hybridoma supernatants and purified mAbs (10), we performed co-incubation assays to insure that differential binding of anti-dsDNA mAbs to BM was not simply a consequence of contaminating chromatin in some but not all hybridoma supernatants. When hybridoma supernatants of mAb pairs 163p.132 and 163p. 124, 452s.46 and 163p.64, 163p.77 and DNA3, and 163p.77 and 452s.160 were assayed for binding to BM, only the mAb that bound to BM in the individual assays, 163p.124, 163p.64, and 163p.77, bound to BM when co-incubated with a non BM-binding mAb ( Fig. 1 and Table 2 ). MAb 163p132 does bind BM but with 100-500-fold less relative affinity than mAbs 163p.64, 77, and 124. The results in Fig 1 corroborate the conclusion that anti-DNA mAb binding to BM is independent of dsDNA or chromatin.
MAb 163p.64 was tested by direct ELISA for binding to individual components of BM, including laminin, perlecan, entactin, and agrin. The mAb bound perlecan, entactin, and agrin (59, 250 , and 220 ng IgG/ml, respectively, for 50% maximum binding) but not laminin. The recombinant agrin did not include the amino-terminal extracellular matrix interaction domains (R&D Systems). Binding to collagen IV was not tested. The results indicate that a BM binding mAb may also bind to some but not all of the individual components of GBM.
In vivo glomerular binding of anti-DNA mAbs
Six purified mAbs were further tested for glomerular binding when injected into non autoimmune-prone BALB/c mice alone or co-injected with a mAb with different BM binding potential and different IgG subclass. The co-injected pairs were 163p. (Table 2 ). The co-injection experiments were included to exclude the possibility that co-purified chromatin or nucleosomes influenced glomerular binding (10) . Only mAbs that bound BM by ELISA, 163p77, 16p.64, and 163p.124, bound glomeruli in vivo when injected either alone or co-injected with a mAb of different IgG subclass (Table 2 and Fig.  2 ). Glomerular binding was unrelated to relative affinity of the mAbs for DNA, chromatin, or mononucleosomes or to IgG subclass.
Confocal microscopy indicated that 163p.64 mAb chronically injected over a 3-month period was co-localized with heparan sulfate proteoglycan (HSPG) in GBM and MM but minimally with chromatin (Fig. 3a) . Glomerular IgG was also co-localized with HSPG and minimally with chromatin in autoimmune BWF1 kidneys (Fig. 3b) . As expected, there was no glomerular binding of anti-DNA mAb 452s.46 after similar 3-months chronic injection (Fig. 3c) . Complement C3 was co-localized with mAb 163p.64 in glomeruli from chronically injected mice (Fig. 3e) . These results indicate that BM-binding anti-DNA antibodies also bind directly to MM and GBM antigens independently of DNA, chromatin, or nucleosomes and initiate complement activation. The small regions of chromatin and IgG co-localization and perlecan, chromatin, and IgG co-localization in the kidneys from BALB/c mice chronically injected with 163p.64 mAb (Fig. 3a) were more numerous in kidneys from autoimmune BWF1 (Fig. 3b) . Those regions of co-localization may be the glomerular EDS identified by electron microscopy in kidneys from autoimmune BWF1 (13) and anti-DNA mAb-injected mice (11) . Table 3) . The difference between 163p.132 injected mice at 5 and 8 days is likely a consequence of much higher mAb serum titer after 8 days. MAb 163p.132 does bind to BM but with 300-fold less relative affinity than mAb 163p.64 (Table 2 ). Alternatively 163p.132 mAb deposition after 8 days may have been due to circulating immune complexes. There was co-localization of 162p.132 mAb with DNA (yellow pixels in Fig. 3f ) although most of the glomerular 163p. 132 IgG was not co-localized with DNA.
Discussion
The present results demonstrate that some but not all anti-DNA mAbs bind directly to BM antigens and that direct binding of anti-dsDNA antibody to GBM or MM is critical for the initiation of experimental lupus nephritis. Glomerular binding of IgG and complement and the initiation of glomerular disease, identified as proteinuria, were independent of mAb binding to DNA or chromatin whether the mAbs were injected or produced in situ. MAb binding to GBM and MM was correlated with relative affinity for dsDNA but independent of binding to DNA or chromatin. Only anti-dsDNA mAbs that bound BM antigens bound to GBM and MM in vivo. These results and conclusion are consistent with previous reports that anti-dsDNA antibodies may initiate glomerulonephritis after binding directly to glomerular antigens (18) (19) (20) (21) (22) (23) (24) . The results and conclusion contrast with results (10-14, 16, 17, 32) interpreted to indicate that anti-DNA antibodies can only bind to GBM or MM as immune complexes of anti-DNA antibody and nucleosomes or by binding to chromatin already bound to GBM or MM (28) (29) (30) . The results from co-injection of mice with a hybridoma producing a BM-binding anti-DNA mAb with a hybridoma producing a non BM-binding anti-DNA mAb are difficult to reconcile with the previous interpretation. MAbs produced by the co-injected hybridomas had similar relative affinity for DNA, nucleosomes, or chromatin, but only the mAbs that bound BM also bound glomeruli in vivo. The results cannot be explained by potential absence of circulating nucleosomes or chromatin in non autoimmune-prone BALB/c mice. Circulating or glomerular-bound chromatin or nucleosomes, including that released from necrotic or apoptotic hybridomas, would have been equally accessible to the two mAbs.
The present results may explain why autoimmune female BWF1 transgenic for V H of the 3H9 anti-DNA mAb (33, 34) do not develop nephritis (35) . 3H9 mAb binds DNA and chromatin (36) but does not bind BM. Autoimmune, 3H9 V H transgenic BWF1 had similar serum IgG 2a/b anti-DNA titers as non-transgenic BWF1 of similar age but did not develop proteinuria even after 1 year of age. Similar outcome was reported for D42 V H (37) and 3-32 μ (38) transgenic BWF1. Non-transgenic, female BWF1 invariably produce anti-DNA autoantibody and develop glomerulonephritis with proteinuria by 10 months of age (1) . BALB/c mice injected with the 3H9 hybridoma had relatively low glomerular immunofluorescence and disease scores compared with mice injected with 163p.77 or 163p. 132 hybridomas (31) . The majority of anti-DNA hybridomas from V H 3H9 transgenic BWF1 had V H 3H9 H chains (39) . Likely those mAbs could not bind BM and could not initiate disease.
Essentially three experimental systems have described nucleosome-dependent glomerular binding of anti-DNA antibodies. Schmiedeke et al. (32) and Termaat et al. (17) allowed soluble DNA to bind to histones after the histones were perfused into kidneys or added to isolated glomeruli or GBM. Anti-DNA mAb bound to the immobilized DNA but not to GBM, histone-coated GBM, or DNA added to GBM. Although interesting, the experiments do not accurately reflect the physical chemical properties of intact nucleosomes, nor how nucleosomes or chromatin may interact with GBM or MM. Kramers et al. (10) reported that purified anti-DNA mAbs perfused into kidneys may only bind in glomeruli as immune complexes with histones or nucleosomes, presenting as example mAb 32. Nucleosomes in the immune complexes were presumed to promote binding to GBM through histonedependent charge interaction. Nucleosomes in physiological saline have a net negative charge with more exposed acidic than basic regions (40, 41) . The basic termini of H2B and H3 that protrude from the octamer cores through the DNA superhelix bind with the acidic patches on the octamer surface of consecutive nucleosomes and with linker DNA to organize the nucleosomes into chromatin (40, 42) . Nucleosomal organization into chromatin precludes surface availability of positive charge contributed by histones (41) . The net charge of the GBM lamina rara interna and externa initially accessible to chromatin or nucleosomes is anionic (43, 44) and unlikely to promote binding. Although nucleosomes bound isolated collagen IV, laminin (15) , and agrin (16) on laboratory sensor chips, radiolabeled nucleosomes (45, 46) were rapidly cleared from blood into the liver with insignificant localization to kidneys unless nucleosome injections were preceded by injection of soluble histones (45) . DNA-anti-DNA immune complexes were likewise rapidly cleared from the circulation (47, 48) . Perfusion into the renal artery (10) would bypass initial circulation to the liver. An alternative explanation for why mAb 32-nucleosome immune complexes bound GBM, but mAb alone did not, might be that the mAb 32 in nucleosome immune complexes had increased relative avidity for GBM. The mAb 32-nucleosome immune complexes were created at a 15:1 molar ratio of mAb to mononucleosome (10) . Multiple unbound antibody combining sites in mAb 32-nucleosome immune complexes prepared in antibody excess may have created higher avidity of the complexes for GBM than mAb 32 alone. The DNA, nucleosome, and BM binding characteristics of mAb 32 were similar to those for mAb 163p.132 in the present study. MAb 163p.132 bound glomeruli only after reaching a serum concentration of ~10 mg/ml. MAbs 163p.64 and 163p.77 that bind with high relative affinity to BM, both bound glomeruli at serum concentrations of ≤720 μg/ml. MAb 163p.132 binds BM but with low relative affinity. Alternatively, the additional 3 days of 163p.132 hybridoma growth from 5 to 8 days may have produced sufficient chromatin or nucleosomes from dying cells to produce immune complexes, likely in mAb excess. There was more glomerular co-localization of DNA with 163p.132 mAb than with the BM-binding 163p.64 mAb.
GBM-associated EDS in kidneys from nephritic BWF1 (13), nephritic lupus patients (12) , and BALB/c mice chronically injected with an anti-DNA mAb (11) contained both chromatin and IgG. The EDS chromatin was presumed to have originated from mesangial cells undergoing apoptosis (13) . The released chromatin was presumed to bind GBM and present target antigens to chromatin-binding antibody. Caspace 3-positive mesangial cells were detected in kidneys from nephritic but not pre-nephritic BWF1 (13), and chromatin was never detected in EDS that did not also contain IgG (11, 13) . Direct binding of nucleosomes or chromatin to GBM was not tested. If chromatin binding to GBM determines when and where anti-DNA antibody binds GBM to initiate EDS, mAbs with similar relative affinity for chromatin should have similar potential to initiate nephritis, which our results show not to be true. Nucleosomes do not bind GBM as discussed above. The recent morphologic studies have elegantly refined our understanding of glomerular EDS in nephritic kidneys (12-14, 16, 49) but fail to clarify how EDS are initiated in lupus nephritis.
Earlier experiments determined that small lattice immune complexes prepared with a cationized antibody were retained within glomerular subendothelial EDS but persisted only when they were able to form larger lattice immune complexes (50) . Glomerular mAb deposition in the present study was independent of mAb pI or immune complexes. Immune complex deposition in GBM can also be initiated by GBM-binding antibody that also binds circulating free antigen to produce immune complexes and EDS (51). Our results are most consistent with this latter mechanism to explain how anti-DNA antibody can initiate glomerular EDS (illustrated in Fig. 4) . The initial event toward glomerular IgG binding and initiation of EDS is direct binding of anti-DNA antibody to GBM or MM (Fig. 4I) . Complement activation and the ensuing inflammation could provide a source for locally released oligonucleosomes. If the locally released oligonucleosomes are bound by GBM or MM-bound antibody (Fig. 4II) (51) , both BM-binding and non BM-binding anti-DNA antibodies could bind the progressively accumulating complex and induce more complement activation, inflammation, and oligonucleosome release (Fig. 4III) . Reduced glomerular DNase I would contribute to and accelerate stage III (Fig. 4) (52) . The progressive accumulation of immune complexes would eventually produce chronic inflammation and lupus nephritis. BM-binding and non BM-binding anti-DNA mAbs were not co-localized in mice 5 days after co-injection with respective hybridomas. There may have been insufficient circulating oligonucleosomes or chromatin from the ascites tumors to generate the glomerular complexes depicted in Fig. 4II . Similarly, 3H9 transgenic BWF1 may fail to develop glomerulonephritis not only because the transgenic anti-DNA antibody cannot bind glomerular antigens, but also because locally released oligonucleosomes are unavailable to create large lattice immune complexes.
Anti-DNA antibodies that bind directly to glomerular endothelial, mesangial, or other cell surface antigens can function similarly to anti-DNA antibodies that bind GBM or MM (19-21, 23, 53-55) . Cell-bound anti-DNA antibodies can initiate inflammation by directly altering cell function, inducing apoptosis or necrosis, or interrupting cell-cell or cell-matrix interactions (6, 56) . Oligonucleosomes released from apoptotic or necrotic cells as a consequence of the induced inflammation can form large lattice immune complexes locally (50) that persist as subendothelial EDS (34).
Our results do not exclude the potential for GBM binding of circulating nucleosomeantibody immune complexes (10) or antibody binding to GBM chromatin, but they do indicate that neither is necessary for BM-binding anti-DNA antibody to bind GBM or MM.
We did not directly test whether injected anti-DNA mAbs would bind differently in nephritic or pre-nephritic BWF1 kidneys compared to BALB/c mouse kidneys. Confocal images of IgG co-localization with GBM and MM in kidneys from 9 month-old BWF1 were similar to those from BALB/c mice chronically injected with BM-binding anti-DNA mAb.
The present results provide additional insight to explain why lupus patients with similar serum antibody to dsDNA or nucleosomes can have different antibody-dependent disease outcomes (6).
Methods
Mice BALB/c mice were purchased from Harlan Sprague-Dawley (Indianapolis, IN) and maintained within the UTHSC Laboratory Animal Care Unit. All experimental protocols were approved by IACUC.
Antibodies and antigens
The generation, DNA specificity, and V-region sequences for the mAbs used in these studies have been described (34, (57) (58) (59) . All hybridomas were derived from autoimmune (NZB × NZW)F 1 mice (BWF1) except 3H9 (34) provided by Drs. M. Weigert and M. Radic (Chicago, IL and Memphis, TN). Matrigel ® (BM) (BD Biosciences, Bedford, MA) is a soluble basement membrane matrix of laminin, collagen IV, HSPG, and entactin (nidogen 1). Only high molecular weight bands corresponding to laminin, collagen IV, entactin, and HSPG were detected after high sensitivity staining of an SDS-PAGE of 12.5 μg of Matrigel ® . DNA, ssDNA, and dsDNA were prepared as described (58) . Chromatin and mononucleosomes were isolated from mouse liver or cultured P3x63-Ag8.653 cells as described (60) . Perlecan (HSPG2) and heparan sulfate were purchased from Sigma-Aldrich (St. Louis, MO), and recombinant human nidogen (entactin) and C-terminal recombinant rat agrin, from R&D Systems, (Minneapolis, MN). Agrin is a heparin sulfate proteoglycan in GBM (61) . Biotinylated goat anti-mouse IgG, IgG 2a , and IgG 2b ; FITC-goat anti-mouse IgG; and FITC-streptavidin were purchased from Southern Biotechnology (Birmingham, AL); alkaline phosphatase-streptavidin, from Jackson Immunoresearch Laboratories (West Grove, PA); biotinylated rat anti-perlecan mAb (clone A7L6), from Lab Vision (Thermo Fisher Scientific, Fremont, CA); Alexa 546-strepatavidin and TO-PRO3 ® DNA dye, from Molecular Probes (Invitrogen, Carlsbad, CA); and anti-C3-FITC, from BD Bioscience.
MAb isolation
MAbs were isolated from hybridoma supernatants by affinity chromatography on protein GSepharose 4B (Invitrogen) essentially as described (10) . MAbs were eluted with glycineHCl, pH 2.8 and immediately neutralized. SDS-PAGE of eluted mAbs stained with a high sensitivity Coomassie (Biorad, Hercules, CA) yielded bands corresponding only to immunoglobulin H and L polypeptides. DNA was not detected in purified mAbs by ethidium bromide staining after agarose electrophoresis but was detected in the high salt eluate.
ELISA for DNA, chromatin, nucleosome, and BM binding
Direct and competitive ELISAs for DNA binding were performed as described (59) . ELISAs for mAb binding to chromatin, nucleosomes, BM, and the BM constituents HSPG, heparan sulfate, and entactin were performed identically to the direct DNA ELISA. Plates (Immulon I, Thermo-Fisher) were coated with DNA, chromatin or mononucleosomes at 1 μg/well DNA; 1/250 dilution of Matrigel ® , ~5 μg/well, estimated as 2.8 μg/well laminin, 1.5 μg/well collagen IV, 0.4 μg/well entactin, and 0.25 μg/well HSPG (BD Bioscience assay); or 0.2 μg/ well of purified BM proteins. Bound IgG from serially diluted supernatant, purified mAb, or serum antibody were detected as described (59) . A biotinylated rat anti-laminin mAb (clone A5) (Neomarkers) was used as a positive control for the anti-BM ELISA. Statistical analyses were performed with PASW Statistics 18 (SPSS Statistics, IBM, Armonk, NY).
In vivo glomerular binding of anti-DNA mAb and measurement of proteinuria
BALB/c mice, eight-to-twelve weeks old, were injected once intravenously with 1 mg of a single, purified mAb or 1 mg each of two purified mAbs, one IgG 2a , the other IgG 2b .
Twenty-four hours later injected mice were euthanized and their kidneys removed and snap frozen in OCT embedding medium (Tissue-Tek, Miles Laboratories, Elkhart, IN). Serial one μm cryosections were fluorescently stained with biotinylated goat anti-mouse IgG 2a or IgG 2b and FITC-streptavidin. In separate experiments, mice were chronically injected with 100 μg per intraperitoneal (ip) injection of a single mAb twice weekly for 3 months or injected ip with hybridoma cells 5-7 days after ip injection with 0.5 ml pristane (Sigma). The hybridoma injection consisted of 10 7 cells from one hybridoma or 10 7 cells each from two hybridomas, one producing IgG 2a and the other, IgG 2b . Kidneys were removed and embedded for cryosection after 3 months chronic injection of purified mAb or 1-5 days after hybridoma injection. Serial cryosections from the same kidney were stained for detection of mouse IgG 2a or IgG 2b . For confocal microscopy 4-12 μm cryosections were stained with TO-PRO3 for DNA, goat anti-mouse IgG-FITC, and rat anti-perlecan and streptavidin Alexa 546 or anti-C3-FITC and biotinylated goat anti-mouse IgG and streptavidin-Alexa 546. Confocal images were collected with a Zeiss LSM510 confocal microscope (Carl Zeiss Microimaging, Thornwood, NY). Proteinuria was measured with Ames Uristix (Miles) according to manufacturer's instructions.
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( Hypothetical mechanism for the initiation of lupus nephritis by BM-binding anti-dsDNA antibody. The stage I to II transition is likely to be reversible (62) . The stage II to III transition associated with the progressive accumulation of antibody and chromatin into immune complexes will eventually reach a threshold for which the immune complex deposition is no longer reversible. This stage would yield chronic inflammation and lupus nephritis. EDS (11, 12, 27) b ng/ml competitor is the amount of dsDNA or ssDNA competitor required to produce 50% inhibition of mAb binding to solid phase DNA in a competitive ELISA (24) . NI = no inhibition with 10,000 ng/ml competitor.
c ng/ml mAb that yields 50% maximum binding in a direct ELISA. NB = no binding with ≥10,000 ng/ml mAb. Table 2 Monoclonal Antibody Binding to DNA, Chromatin, and Basement Membrane Antigens. e Glomerular binding of mAb was determined by immunofluorescence on kidney cryosections 24 hrs after mice were injected with 1 mg purified mAb(s).
f Summary of results presented in Table 3 . Table 3 Hybridomas producing BM-binding mAb induce proteinuria. e Proteinuria measured on the indicated days after hybridoma injection.
